VKH
JUNO

Virtu KCG Holdings’s Juno Therapeutics, Inc. JUNO Stock Holding History

Virtu KCG Holdings’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-19,763
Closed -$373K – 4102
2016
Q4 		$373K Sell
19,763
-11,261
-36% -$276K 0.01% 1844
2016
Q3 		$931K Buy
+31,024
New +$965K 0.02% 759
2016
Q2 		– Sell
-11,810
Closed -$450K – 3558
2016
Q1 		$450K Buy
11,810
+4,471
+61% +$156K 0.01% 1305
2015
Q4 		$323K Buy
+7,339
New +$364K 0.01% 2063

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Virtu KCG Holdings's JUNO Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 19,763 shares — an estimated $373K sold.

Virtu KCG Holdings first reported a position in JUNO in Q4 2015 and held it in 4 quarters. The position peaked at $931K in Q3 2016. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

  • Virtu KCG Holdings reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 19,763 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $373K.
  • Virtu KCG Holdings first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 4 quarters.
  • Virtu KCG Holdings's Juno Therapeutics, Inc. position peaked at $931K in Q3 2016.
  • 157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.